Table 3 Physician-stated choices for management of prostate cancer patients who no longer respond to their first LHRH agonist
Therapy prescribed | France (n = 23) | Germany (n = 31) | Italy (n = 17) | Spain (n = 14) | UK (n = 30) | Total (n = 115) |
|---|---|---|---|---|---|---|
LHRH agonist + anti-androgen | 8 (35) | 13 (42) | 12 (71) | 3 (21) | 21 (70) | 57 (50) |
LHRH agonist alone | 6 (26) | 9 (29) | 4 (24) | 2 (14) | 2 (7) | 23 (20) |
Anti-androgen alone | 3 (13) | 7 (23) | 0 (0) | 7 (50) | 5 (17) | 22 (19) |
Other* | 6 (26) | 2 (6) | 1 (6) | 2 (14) | 2 (7) | 13 (11) |